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Activation of the anaplastic lymphoma kinase (ALK) gene has been described through chromosomal rearrangements, resulting in the placement of different 5′ fusion part-
ners and their associated promoter region upstream of the kinase domain of ALK. ALK 
was originally identified in anaplastic large cell lymphoma as a fusion protein to nucleo-
phosmin.1 Echinoderm microtubule-associated protein like 4 (EML4)–ALK was the first 
targetable fusion oncokinase to be identified in 4 to 6% of non–small-cell lung cancer 
(NSCLC).2 Crizotinib, an oral small-molecule inhibitor of ALK and c-Met receptor kinases, 
is now approved for the treatment of ALK positive advanced NSCLC, based on two pivotal 
studies.3,4 To ensure identification of patients who are most likely to benefit, the Food and 
Drug Administration approved crizotinib concurrently with a diagnostic test – the Vysis 
ALK Break Apart FISH Probe Kit – that has become the gold standard for detecting ALK 
rearrangements. Although ALK FISH is clinically validated, the assay can be technically 
challenging. Therefore, other diagnostic modalities are being explored, including immuno-
histochemistry (IHC) and reverse transcriptase–polymerase chain reaction (RT-PCR).
In this issue of Journal of Thoracic Oncology, Sholl et al. demonstrate strong asso-
ciation between ALK IHC and FISH, arguing for a combined FISH and IHC approach to 
maximize the sensitivity and specificity of detection of ALK-rearranged NSCLC.5 ALK 
IHC was 93% sensitive and 100% specific as compared with FISH.5 Using the Vysis ALK 
Break Apart FISH Probe Kit, they performed ALK FISH testing in 830 cases and found 
25 cases (3%) demonstrating an ALK rearrangement.5 Of these, 186 cases, including 15 
FISH-positive cases, were tested by ALK IHC using the clone 5A4.5 ALK protein expres-
sion was detected in 13 cases whereas 12 IHC-positive cases showed an ALK rearrange-
ment by FISH.5
In our routine assessment of ALK by FISH, we observe the variability in the percent-
age of positive cells in ALK-rearranged tumors. In theory, FISH can detect any inter- or 
intrachromosomal lesion involving ALK. However the “split” signal characteristic of an 
EML4–ALK fusion can be subtle, due to the loss and inversion of only a small amount 
of genetic material on chromosome 2. In addition, the destruction of tissue structure by 
formalin fixation can complicate FISH analysis. Thus, although FISH is a sensitive and 
specific means to detect ALK rearrangements in NSCLC, it is not infallible. In a recent 
study, a dramatic response to crizotinib in a NSCLC patient with IHC-positive (clone 5A4) 
and FISH-negative ALK tumor has been reported.6
Unlike RT-PCR, FISH cannot distinguish between the different EML4–ALK fusion 
variants. As EML4 and ALK are mapped to chromosome 2p in opposite directions in normal 
cells, a set of PCR primers will not generate any specific PCR product from cDNA of 
normal cells or of cancer without inv(2)(p21p23).7 Therefore, RT-PCR can become a highly 
sensitive detection method for EML4–ALK-positive tumors. Soda et al. have detected 
EML4–ALK mRNA by multiplex RT-PCR.8 The accuracy of RT-PCR–based diagnosis 
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depends markedly on the RNA quality of specimens although 
there is a large variation in the PCR cycle number required 
for successful amplification among specimens.8 Moreover, 
RT-PCR can be readily applied to specimens such as sputum, 
bronchial washing fluid, or pleural effusion that may not be 
suitable for preparation of formalin-fixed paraffin-embedded 
samples.8
Unlike observations in ALK positive lymphomas, 
NSCLC specimens express a low amount of the EML4–ALK 
fusion protein that IHC performed with the commercially 
available antibodies is unable to detect. This finding, coupled 
with reports that tumors can express EML4–ALK transcript 
in the absence of ALK protein, raises questions as to whether 
ALK protein is invariably expressed by tumors harboring an 
EML4–ALK fusion, and whether IHC is a reliable diagnostic 
test. ALK IHC is less time consuming, is cost effective, can 
be performed on small biopsies, and theoretically, can identify 
all EML4–ALK variants or even other ALK fusions.9 The first 
antibody against ALK was the ALK1 clone provided by Dako 
which suffers from low sensitivity.10 Other ALK monoclonal 
antibodies, like the SP8 and the 5A4 clone, the ZAL4 and the 
P80, or the rabbit D5F, have been tested, but with the excep-
tion of the clone 5A4, the others are questionable and unable 
to stain all the variants detected by RT-PCR.7,11–13 A caveat is 
that tissue staining for ALK, even with the most sensitive of 
IHC tests, may be weak and focal in the biopsy sections and 
confirmatory FISH studies should be considered. Sholl et al. 
commend that they cannot draw definite conclusions about the 
true sensitivity and specificity of FISH and IHC in predicting 
response to crizotinib therapy and prompt the incorporation of 
prospective IHC and FISH analysis in clinical diagnostics to 
help them address this issue.5
Four discrepant ALK FISH and ALK IHC cases are 
described in this issue of Journal of Thoracic Oncology.5 In 
the first two cases, in which ALK translocation was false-
positive by FISH at diagnosis, additional driver mutations in 
exon 15 of BRAF and in exon 21 of EGFR were detected.5 
Interestingly, in the case of the patient with an ALK rearrange-
ment and EGFR mutation, careful analysis of the FISH results 
in the tumor recurrence revealed an atypical rearrangement 
characterized by an asymmetric splitting of the 5′ probe.5 
The authors note that it is important to determine whether in 
patients with dual driver alterations, the detected rearrange-
ment was either a technical artifact or, if indeed present, was 
possibly not transcribed or translated and was lost during 
disease progression, reflecting the biology around the driver 
mutation.5 Additional studies are required to elucidate the 
concurrent genetic events necessary for EML4–ALK to exert 
an oncogenic function.
The data in this article show that ALK IHC improves 
the detection of ALK rearrangements when used together 
with FISH and is correctly indicated that ALK FISH 
testing is prone to false-negative and false-positive results. 
However, there are still many issues to be considered. Do all 
the EML4–ALK variants respond in the same way to ther-
apy? Is the response to treatment the same for EML4–ALK 
rearranged tumors and those containing another fusion? 
The demonstration of the existence of multiple isoforms 
of EML4–ALK transcripts will necessitate optimization of 
detection systems so that all isoforms are detected with high 
accuracy and sensitivity. Issues concerning the frequency, 
heterogeneity, and tissue specificity of the EML4–ALK 
rearrangement must also be addressed carefully. Other tech-
niques, especially RT-PCR or sequencing can help us to 
understand better the biology of the various ALK fusions 
and may lead us one step more in targeted therapy. Without 
doubt, high throughput sequencing methodologies will also 
be very helpful.
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